百濟神州(06160.HK):第三季度總收入達7.81億美元 同比增長102%
格隆匯11月10日丨百濟神州(06160.HK)發佈公吿,2023年第三季度,本季度總收入達7.81億美元,全球產品收入達5.95億美元,分別同比增長102%和70%,同時,穩步提升經營槓桿效益。得益於在美國和歐盟的上市工作,百悦澤®全球銷售額達3.58億美元,同比增長130%。第三季度內,淨利潤為2.154億美元。
百濟神州聯合創始人、董事長兼首席執行官歐雷強(John V. Oyler)先生表示:“我們的團隊本季度在全球產品組合中再次取得強勁的業績,這得益於百悦澤®持續的成功上市,包括在慢性淋巴細胞白血病(CLL)等所有已獲批適應症中不斷取得快速應用。我們很高興重新獲得了百澤安®的全球權利,這一款藥品現已在歐盟獲批,同時還在其他10個市場推進監管審評。我們現在比以往任何時候更能推進全球增長策略,與此同時,穩步提升經營槓桿效益,並控制費用增長。”
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.